Journal of Menopausal Medicine

The Korean Society of Menopause (대한폐경학회)
권호 표지
DOI QR코드

DOI QR Code

The Role of Menopausal Hormone Therapy in Reducing All-cause Mortality in Postmenopausal Women Younger than 60 Years: An Adaptive Meta-analysis

  • Bae, Jong-Myon (Department of Preventive Medicine, Jeju National University School of Medicine) ;
  • Yoon, Byung-Koo (Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine)
  • Received : 2018.08.06
  • Accepted : 2018.10.11
  • Published : 2018.12.31
⟨ Previous Next ⟩

Abstract

Keywords

References

  1. Santen RJ, Allred DC, Ardoin SP, Archer DF, Boyd N, Braunstein GD, et al. Postmenopausal hormone therapy: an Endocrine Society scientific statement. J Clin Endocrinol Metab 2010; 95: s1-s66. https://doi.org/10.1210/jc.2009-2509
  2. Boardman HM, Hartley L, Eisinga A, Main C, Roque i Figuls M, Bonfill Cosp X, et al. Hormone therapy for preventing cardiovascular disease in post-menopausal women. Cochrane Database Syst Rev 2015; 3: CD002229.
  3. Schierbeck LL, Rejnmark L, Tofteng CL, Stilgren L, Eiken P, Mosekilde L, et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ 2012; 345: e6409. https://doi.org/10.1136/bmj.e6409
  4. Veerus P, Hovi SL, Fischer K, Rahu M, Hakama M, Hemminki E. Results from the estonian postmenopausal hormone therapy trial [ISRCTN35338757]. Maturitas 2006; 55: 162-73. https://doi.org/10.1016/j.maturitas.2006.01.012
  5. Nachtigall LE, Nachtigall RH, Nachtigall RD, Beckman EM. Estrogen replacement therapy II: a prospective study in the relationship to carcinoma and cardiovascular and metabolic problems. Obstet Gynecol 1979; 54: 74-9. https://doi.org/10.1097/00006250-197907000-00017
  6. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321-33. https://doi.org/10.1001/jama.288.3.321
  7. Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004; 291: 1701-12. https://doi.org/10.1001/jama.291.14.1701
  8. Gartlehner G, Patel SV, Viswanathan M, Feltner C, Weber RP, Lee R, et al. U.S. preventive services task force evidence syntheses, formerly systematic evidence reviews. In: Agency for Healthcare Research and Quality, editor. Hormone therapy for the primary prevention of chronic conditions in postmenopausal women: An evidence review for the U.S. preventive services task force. Rockville (MD): Agency for Healthcare Research and Quality; 2017. pp.15-05227-EF-1.
  9. LaCroix AZ, Chlebowski RT, Manson JE, Aragaki AK, Johnson KC, Martin L, et al. Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA 2011; 305: 1305-14. https://doi.org/10.1001/jama.2011.382
  10. Grossman DC, Curry SJ, Owens DK, Barry MJ, Davidson KW, Doubeni CA, et al. Hormone therapy for the primary prevention of chronic conditions in postmenopausal women: US preventive services task force recommendation statement. JAMA 2017; 318: 2224-33. https://doi.org/10.1001/jama.2017.18261
  11. Bae JM, Kim EH. Citation discovery tools for conducting adaptive meta-analyses to update systematic reviews. J Prev Med Public Health 2016; 49: 129-33. https://doi.org/10.3961/jpmph.15.074
  12. Manson JE, Aragaki AK, Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, et al. Menopausal hormone therapy and long-term all-cause and cause-specific mortality: The women's health initiative randomized trials. JAMA 2017; 318: 927-38. https://doi.org/10.1001/jama.2017.11217
  13. Cherry N, McNamee R, Heagerty A, Kitchener H, Hannaford P. Long-term safety of unopposed estrogen used by women surviving myocardial infarction: 14-year follow-up of the ESPRIT randomised controlled trial. BJOG 2014; 121: 700-5. https://doi.org/10.1111/1471-0528.12598
  14. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998; 280; 605-13. https://doi.org/10.1001/jama.280.7.605
  15. Hulley S, Furberg C, Barrett-Connor E, Cauley J, Grady D, Haskell W, et al. Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 2002; 288: 58-66. https://doi.org/10.1001/jama.288.1.58
  16. Bibbins-Domingo K, Lin F, Vittinghoff E, Barrett-Connor E, Hulley SB, Grady D, et al. Effect of hormone therapy on mortality rates among women with heart failure and coronary artery disease. Am J Cardiol 2005; 95: 289-91. https://doi.org/10.1016/j.amjcard.2004.09.021
  17. Bae JM, Lee EJ, Guyatt G. Citrus fruit intake and stomach cancer risk: a quantitative systematic review. Gastric Cancer 2008; 11: 23-32. https://doi.org/10.1007/s10120-007-0447-2
  18. Shim SR, Shin IS, Bae JM. Intervention meta-analysis using STATA software. J Health Info Stat 2016; 41: 123-34. https://doi.org/10.21032/jhis.2016.41.1.123

Cited by

  1. Risks and benefits of menopausal hormone therapy vol.62, pp.3, 2018, https://doi.org/10.5124/jkma.2019.62.3.150
  2. Ovariectomy Activates Chronic Low‐Grade Inflammation Mediated by Memory T Cells, Which Promotes Osteoporosis in Mice vol.35, pp.6, 2018, https://doi.org/10.1002/jbmr.3966
  3. A Review of Pharmacological Treatments for Vaginal Atrophy in Postmenopausal Women in Iran vol.26, pp.2, 2018, https://doi.org/10.6118/jmm.19021